Across TCGA pan-cancer cohorts, FAM153B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FAM153B data layer compared with 20 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher FAM153B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM153B expression acts as an unfavorable survival marker.
BLCA and LIHC are the cancer types where FAM153B Mutation most reproducibly stratifies survival.